Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy

ClinicalTrials.gov ID: NCT00686920

Public ClinicalTrials.gov record NCT00686920. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 2:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Open-Label Trial to Evaluate the Long-Term Safety and Tolerability of Rifaximin 550 mg BID in Subjects With a History of Hepatic Encephalopathy

Study identification

NCT ID: NCT00686920
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bausch Health Americas, Inc.; Industry
Enrollment: 322 participants

Conditions and interventions

Conditions

Hepatic Encephalopathy

Interventions

Rifaximin Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 6, 2007
Primary completion: Dec 7, 2010
Completion: Dec 7, 2010
Last update posted: Aug 13, 2019

2007 – 2010

United States locations

U.S. sites: 31
U.S. states: 18
U.S. cities: 31

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	—	—
Not listed	Aurora	California	—	—
Not listed	Fresno	California	—	—
Not listed	La Jolla	California	—	—
Not listed	Long Beach	California	—	—
Not listed	Los Angeles	California	—	—
Not listed	Merced	California	—	—
Not listed	Sacramento	California	—	—
Not listed	San Francisco	California	—	—
Not listed	Golden	Colorado	—	—
Not listed	Washington D.C.	District of Columbia	—	—
Not listed	Macon	Georgia	—	—
Not listed	Iowa City	Iowa	—	—
Not listed	Monroe	Louisiana	—	—
Not listed	Boston	Massachusetts	—	—
Not listed	Detroit	Michigan	—	—
Not listed	Kansas City	Missouri	—	—
Not listed	Lebanon	New Hampshire	—	—
Not listed	Bayside	New York	—	—
Not listed	New York	New York	—	—
Not listed	Rochester	New York	—	—
Not listed	Asheville	North Carolina	—	—
Not listed	Charlotte	North Carolina	—	—
Not listed	Cincinnati	Ohio	—	—
Not listed	Cleveland	Ohio	—	—
Not listed	Philadelphia	Pennsylvania	—	—
Not listed	Houston	Texas	—	—
Not listed	Odessa	Texas	—	—
Not listed	San Antonio	Texas	—	—
Not listed	Richmond	Virginia	—	—
Not listed	Madison	Wisconsin	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00686920, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 13, 2019 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00686920 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →